This invention relates generally to devices and methods for shaping tissue by deploying one or more devices in body lumens adjacent to the tissue. One particular application of the invention relates to a treatment for mitral valve regurgitation through deployment of a tissue shaping device in the patient's coronary sinus or great cardiac vein.
The mitral valve is a portion of the heart that is located between the chambers of the left atrium and the left ventricle. When the left ventricle contracts to pump blood throughout the body, the mitral valve closes to prevent the blood being pumped back into the left atrium. In some patients, whether due to genetic malformation, disease or injury, the mitral valve fails to close properly causing a condition known as regurgitation, whereby blood is pumped into the atrium upon each contraction of the heart muscle. Regurgitation is a serious, often rapidly deteriorating, condition that reduces circulatory efficiency and must be corrected.
Two of the more common techniques for restoring the function of a damaged mitral valve are to surgically replace the valve with a mechanical valve or to suture a flexible ring around the valve to support it. Each of these procedures is highly invasive because access to the heart is obtained through an opening in the patient's chest. Patients with mitral valve regurgitation are often relatively frail thereby increasing the risks associated with such an operation.
One less invasive approach for aiding the closure of the mitral valve involves the placement of a tissue shaping device in the cardiac sinus and vessel that passes adjacent the mitral valve. The tissue shaping device is designed to push the vessel and surrounding tissue against the valve to aid its closure. This technique has the advantage over other methods of mitral valve repair because it can be performed percutaneously without opening the chest wall. Examples of such devices are shown in U.S. patent application Ser. No. 10/142,637, “Body Lumen Device Anchor, Device and Assembly” filed May 8, 2002; U.S. patent application Ser. No. 10/331,143, “System and Method to Effect the Mitral Valve Annulus of a Heart” filed Dec. 26, 2002; and U.S. patent application Ser. No. 10/429,172, “Device and Method for Modifying the Shape of a Body Organ,” filed May 2, 2003. The disclosures of these patent applications are incorporated herein by reference.
When deploying a tissue shaping device in a vein or artery to modify adjacent tissue, care must be taken to avoid constricting nearby arteries. For example, when treating mitral valve regurgitation, a tissue shaping device may be deployed in the coronary sinus to modify the shape of the adjacent mitral valve annulus. Coronary arteries such as the circumflex artery may cross between the coronary sinus and the heart, however, raising the danger that deployment of the support may limit perfusion to a portion of the heart by constricting one of those arteries. See, e.g., the following applications, the disclosures of which are incorporated herein by reference: U.S. patent application Ser. No. 09/855,945, “Mitral Valve Therapy Device, System and Method,” filed May 14, 2001 and published Nov. 14, 2002, as US 2002/0169504 A1; U.S. patent application Ser. No. 09/855,946, “Mitral Valve Therapy Assembly and Method,” filed May 14, 2001 and published Nov. 14, 2002, as US 2002/0169502 A1; and U.S. patent application Ser. No. 10/003,910, “Focused Compression Mitral Valve Device and Method” filed Nov. 1, 2001. It is therefore advisable to monitor cardiac perfusion during and after such mitral valve regurgitation therapy. See, e.g., U.S. patent application Ser. No. 10/366,585, “Method of Implanting a Mitral Valve Therapy Device,” filed Feb. 12, 2003, the disclosure of which is incorporated herein by reference.
The anatomy of the heart and its surrounding vessels varies from patient to patient. For example, the location of the circumflex artery and other key arteries with respect to the coronary sinus can vary. Specifically, the distance along the coronary sinus from the ostium to the crossing point with the circumflex artery can vary from patient to patient. In addition, the diameter and length of the coronary sinus can vary from patient to patient.
We have invented a tissue shaping device, a set of tissue shaping devices and a method that maximize the therapeutic effect (i.e., reduction of mitral valve regurgitation) while minimizing adverse effects, such as an unacceptable constriction of the circumflex artery or other coronary arteries. The tissue shaping device, set of devices and method of this invention enable the user to adapt the therapy to the patient's anatomy.
One aspect of the invention is a method of treating mitral valve regurgitation in a patient. The method includes the steps of delivering a tissue shaping device to the patient's coronary sinus in an unexpanded configuration within a catheter having an outer diameter no more than nine or ten french, with the tissue shaping device including a connector disposed between a distal expandable anchor comprising flexible wire and a proximal expandable anchor comprising flexible wire, the device having a length of 60 mm or less; and deploying the device to reduce mitral valve regurgitation, such as by anchoring the distal expandable anchor by placing the distal expandable anchor flexible wire in contact with a wall of the coronary sinus, e.g., by permitting the distal expandable anchor to self-expand or by applying an actuating force to the distal expandable anchor and possibly locking the distal expandable anchor after performing the applying step. The deploying step may include the step of anchoring the distal expandable anchor with an anchoring force of at least one to two pounds.
In some embodiments, the method's deploying step further includes the step of applying a proximally directed force on the distal expandable anchor through the connector, possibly from outside the patient, such as by moving the proximal anchor proximally with respect to the coronary sinus. The method may also include the step of anchoring the proximal anchor, either before or after the step of applying a proximally directed force on the distal expandable anchor and before or after the moving step. The proximal anchor may be anchored by permitting the proximal expandable anchor to self-expand or by applying an actuating force to the proximal expandable anchor and possibly locking the proximal expandable anchor after performing the applying step.
In some embodiments, such as embodiments in which the distal expandable anchor also includes a distal expandable anchor flexible wire connection substantially limiting proximal and distal movement of the connection with respect to the distal expandable anchor, the delivering step includes the step of delivering the tissue shaping device to the coronary sinus in an unexpanded configuration in which none of the distal expandable anchor flexible wire extends proximally along the connector within the catheter.
In other embodiments, such as embodiments in which the distal expandable anchor also includes a distally and proximally movable distal expandable anchor flexible wire connection, the delivering step may include the step of delivering the tissue shaping device to the coronary sinus in an unexpanded configuration in which at least a portion of the distal expandable anchor flexible wire extends proximally or distally along the connector within the catheter. The deploying step in those embodiments may include the steps of moving the connection distally to actuate the distal expandable anchor and locking the distal expandable anchor after performing the moving step.
Another aspect of the invention is a tissue shaping device adapted to be delivered to a coronary sinus in an unexpanded configuration within a catheter having an outer diameter of no more than nine to ten french and further adapted to be deployed in the coronary sinus to reduce mitral valve regurgitation, with the device including a connector disposed between a distal expandable anchor comprising a flexible wire (such as a self-expanding anchor or an actuatable anchor possibly having an actuator and a lock) and a proximal expandable anchor comprising a flexible wire, the device having a length of 60 mm or less. In some embodiments the distal expandable anchor is adapted to conform to a range of coronary sinus diameters by expanding to contact a wall portion of the coronary sinus to provide an anchoring force sufficient to anchor the device within the coronary sinus, such as an anchoring force of at least one to two pounds.
In some embodiments the device has an expanded configuration, with the distal expandable anchor having at least one or two bending points and first and second arms extending from the bending points, the first and second arms being adapted to deform about the bending points when the device moves from the expanded configuration to the unexpanded configuration. The bending points may be disposed at the tallest point of the distal expandable anchor when the distal expandable anchor is in the expanded configuration. The first and second arms may extend generally proximally or generally distally when the tissue shaping device is in the unexpanded configuration. The bending point may be, e.g., a section of the flexible wire having an increased radius of curvature compared to adjacent wire sections or a loop formed in the flexible wire, and may be disposed on the distal or proximal side of the anchor.
The device may also include a distal expandable anchor flexible wire connection substantially limiting proximal and distal movement of the connection with respect to the distal expandable anchor or a distally and proximally movable connection between the distal expandable anchor and the connector. The device may also be adapted to be recaptured from its expanded configuration within the coronary sinus to an unexpanded configuration within a catheter within the coronary sinus and possibly redeployed in the coronary sinus after being recaptured.
In some embodiments the proximal anchor is adapted to conform to a range of coronary sinus diameters by expanding to contact a wall portion of the coronary sinus with an anchoring force sufficient to anchor the device within the coronary sinus. In embodiments in which the device has an expanded configuration, the proximal anchor may include at least one bending point and first and second arms extending from the bending point, the first and second arms being adapted to deform about the bending point when the device moves from the expanded configuration to the unexpanded configuration. The proximal anchor may be a self-expanding anchor or an actuatable anchor, in which case the actuatable anchor may include an actuator and a lock adapted to lock the actuator in a deployed position.
The invention will be described in more detail below with reference to the drawings.
Disposed within the coronary sinus 12 is a tissue shaping device 30. As shown in
In the embodiment of
According to one preferred embodiment, the device is deployed as far distally as possible without applying substantial compressive force on the circumflex or other major coronary artery. Thus, the distal end of catheter 50 is disposed at a distal anchor location proximal of the crossover point between the circumflex artery 24 and the coronary sinus 12 as shown in
Distal anchor 34 is either a self-expanding anchor or an actuatable anchor or a combination self-expanding and actuatable anchor. Once uncovered, distal anchor 34 self-expands, or is expanded through the application of an actuation force (such as a force transmitted through control wire 52), to engage the inner wall of coronary sinus 12, as shown in
While device 30 is held in place by the anchoring force of distal anchor 34, catheter 50 is withdrawn further proximally to a point just distal of proximal anchor 36, as shown in
After the appropriate amount of reduction in mitral valve regurgitation has been achieved (as determined, e.g., by viewing doppler-enhanced echocardiograms), the proximal anchor is deployed. Other patient vital signs, such as cardiac perfusion, may also be monitored during this procedure as described in U.S. patent application Ser. No. 10/366,585.
In preferred embodiments, the proximal anchor's anchoring force, i.e., the force with which the proximal anchor resists moving in response to a distally-directed force, must be sufficient not only to maintain the device's position within the coronary sinus but also to enable the device to maintain the adjacent tissue's cinched shape. In a preferred embodiment, the proximal anchor engages the coronary sinus wall to provide an anchoring force of at least one pound, most preferably an anchoring force of at least two pounds. As with the distal anchor, the proximal anchor's expansion energy to supply the anchoring force comes from strain energy stored in the anchor due to its compression for catheter delivery, from an actuation force, or a combination of both, depending on anchor design.
In a preferred embodiment, the proximal anchor is deployed by withdrawing catheter 50 proximally to uncover proximal anchor 36, then either permitting proximal anchor 36 to self-expand, applying an actuation force to expand the anchor, or a combination of both. The control wire 52 is then detached, and catheter 50 is removed from the patient. The device location and configuration as deployed according to this method is as shown in
Alternatively, proximal anchor 36 may be deployed at least partially outside of the coronary sinus after cinching to modify the shape of the mitral valve tissue, as shown in
In alternative embodiments, the proximal anchor may be deployed prior to the application of the proximally directed force to cinch the device to reshape the mitral valve tissue. One example of a device according to this embodiment is shown in
It may be desirable to move and/or remove the tissue shaping device after deployment or to re-cinch after initial cinching. According to certain embodiments of the invention, therefore, the device or one of its anchors may be recaptured. For example, in the embodiment of
Alternatively, catheter 50 may be advanced distally to recapture both proximal anchor 36 and distal anchor 34, e.g., to the configuration shown in
Fluoroscopy (e.g., angiograms and venograms) may be used to determine the relative positions of the coronary sinus and the coronary arteries such as the circumflex artery, including the crossover point between the vessels and whether or not the artery is between the coronary sinus and the heart. Radiopaque dye may be injected into the coronary sinus and into the arteries in a known manner while the heart is viewed on a fluoroscope.
An alternative method of determining the relative positions of the vessels is shown in
In one embodiment of the invention, connector 102 comprises a double length of nitinol wire that has both ends positioned within a distal crimp tube 108. Proximal to the proximal end of the crimp tube 108 is a distal lock bump 110 that is formed by the support wire bending away from the longitudinal axis of the support 102 and then being bent parallel to the longitudinal axis of the support before being bent again towards the longitudinal axis of the support to form one half 110a of distal lock bump 110. From distal lock bump 110, the wire continues proximally through a proximal crimp tube 112. On exiting the proximal end of the proximal crimp tube 112, the wire is bent to form an arrowhead-shaped proximal lock bump 114. The wire of the support 102 then returns distally through the proximal crimp tube 112 to a position just proximal to the proximal end of the distal crimp tube 108 wherein the wire is bent to form a second half 110b of the distal lock 110.
At the distal end of connector 102 is an actuatable distal anchor 120 that is formed of a flexible wire such as nitinol or some other shape memory material. As shown in
The distal anchor is expanded by using a catheter or locking tool to exert an actuation force sliding eyelet 122 of the distal anchor from a position that is proximal to distal lock bump 110 on the connector to a position that is distal to distal lock bump 110. The bent-out portions 110a and 110b of connector 110 are spaced wider than the width of eyelet 122 and provide camming surfaces for the locking action. Distal movement of eyelet 122 pushes these camming surfaces inward to permit eyelet 122 to pass distally of the lock bump 110, then return to their original spacing to keep eyelet 122 in the locked position.
Actuatable proximal anchor 140 is formed and actuated in a similar manner by moving eyelet 142 over lock bump 114. Both the distal and the proximal anchor provide anchoring forces of at least one pound, and most preferably two pounds.
Because of the inherent elasticity of the material from which it is formed, the distal anchor begins to expand as soon as it is outside the catheter. Once the device is properly positioned, catheter 200 is advanced to place an actuation force on distal anchor eyelet 122 to push it distally over the distal lock bump 110 so that the distal anchor 120 further expands and locks in place to securely engage the wall of the coronary sinus. Next, a proximally-directed force is applied to connector 102 and distal anchor 120 via a tether or control wire 201 extending through catheter outside the patient to apply sufficient pressure on the tissue adjacent the connector to modify the shape of that tissue. In the case of the mitral valve, fluoroscopy, ultrasound or other imaging technology may be used to see when the device supplies sufficient pressure on the mitral valve to aid in its complete closure with each ventricular contraction without otherwise adversely affecting the patient.
The proximally directed reshaping force causes the proximal anchor 140 to move proximally. In one embodiment, for example, proximal anchor 140 can be moved about 1-6 cm., most preferably at least 2 cm., proximally to reshape the mitral valve tissue. The proximal anchor 140 is then deployed from the catheter and allowed to begin its expansion. The locking tool applies an actuation force on proximal anchor eyelet 142 to advance it distally over the proximal lock bump 114 to expand and lock the proximal anchor, thereby securely engaging the coronary sinus wall to maintain the proximal anchor's position and to maintain the reshaping pressure of the connector against the coronary sinus wall. Alternatively, catheter 200 may be advanced to lock proximal anchor 140.
Finally, the mechanism for securing the proximal end of the device can be released. In one embodiment, the securement is made with a braided loop 202 at the end of tether 201 and a lock wire 204. The lock wire 204 is withdrawn thereby releasing the loop 202 so it can be pulled through the proximal lock bump 114 at the proximal end of device 100.
Reduction in mitral valve regurgitation using devices of this invention can be maximized by deploying the distal anchor as far distally in the coronary sinus as possible. In some instances it may be desirable to implant a shorter tissue shaping device, such as situations where the patient's circumflex artery crosses the coronary sinus relatively closer to the ostium or situations in which the coronary sinus itself is shorter than normal. As can be seen from
Likewise, if distal anchor were to be recaptured into a catheter for redeployment or removal from the patient, anchor 300 would deform about bending points 310 to limit the cross-sectional profile of the anchor within the catheter, even if eyelet 306 were not moved proximally over lock bump 308 during the recapture procedure. Bending points may also be provided on the proximal anchor in a similar fashion.
As stated above, distal anchor 300 may be part of a tissue shaping device (such as that shown in
One aspect of anchor 300 is its ability to conform and adapt to a variety of vessel sizes. For example, when anchor 300 is expanded inside a vessel such as the coronary sinus, the anchor's wire arms may contact the coronary sinus wall before the eyelet 306 has been advanced distally over lock bump 308 to lock the anchor in place. While continued distal advancement of eyelet 306 will create some outward force on the coronary sinus wall, much of the energy put into the anchor by the anchor actuation force will be absorbed by the deformation of the distal struts about bending points 310, which serve as expansion energy absorption elements and thereby limit the radially outward force on the coronary sinus wall. This feature enables the anchor to be used in a wider range of vessel sizes while reducing the risk of over-expanding the vessel.
Likewise, if distal anchor were to be recaptured into a catheter for redeployment or removal from the patient, anchor 320 would deform about bending points 330 to limit the cross-sectional profile of the anchor within the catheter. Bending points may also be provided on the proximal anchor in a similar fashion.
Distal anchor 320 may be part of a tissue shaping device (such as that shown in
Distal anchor 340 may be part of a tissue shaping device (such as that shown in
Bending points 350 also add to the anchoring force of distal anchor 340, e.g., by causing the anchor height to increase as the proximal struts become more perpendicular to the connector in response to a proximally directed force, thereby increasing the anchoring force. In the same manner, bending points may be added to the distal struts of a proximal anchor to increase the proximal anchor's anchoring force in response to a distally directed force.
Anchor 360 may be used as part of a tissue shaping device like the embodiments discussed above.
If distal anchor were to be recaptured into a catheter for redeployment or removal from the patient, anchor 380 would deform about bending points 390 to limit the cross-sectional profile of the anchor within the catheter, even if eyelets 386 and 387 were not moved proximally over lock bump 388 during the recapture procedure. Bending points may also be provided on the proximal anchor in a similar fashion.
As with the other embodiments above, distal anchor 380 may be part of a tissue shaping device (such as that shown in
As with other embodiments, one aspect of anchor 380 is its ability to conform and adapt to a variety of vessel sizes. For example, when anchor 380 is expanded inside a vessel such as the coronary sinus, the anchor's wire arms may contact the coronary sinus wall before the eyelets 386 and 387 have been advance distally over lock bump 388 to lock the anchor in place. While continued distal advancement of eyelet 386 will create some outward force on the coronary sinus wall, much of the energy put into the anchor by the anchor actuation force will be absorbed by the deformation of the distal struts about bending points 390.
Like other embodiments, one aspect of anchor 400 is its ability to conform and adapt to a variety of vessel sizes. For example, when anchor 400 is expanded inside a vessel such as the coronary sinus, the anchor's wire arms may contact the coronary sinus wall before the eyelet 406 has been advanced distally over lock bump 408 to lock the anchor in place. While continued distal advancement of eyelet 406 will create some outward force on the coronary sinus wall, much of the energy put into the anchor by the anchor actuation force will be absorbed by the deformation of the distal struts about bending points 410, which serve as expansion energy absorption elements and thereby limit the radially outward force on the coronary sinus wall.
In other embodiments, the looped bending points of the
As in the other embodiments, anchor 440 is preferably formed from nitinol wire. Anchor 440 may be used as part of a tissue shaping device in a manner similar to the anchor of
As in the other embodiments, anchor 460 is preferably formed from nitinol wire. Anchor 460 may be used as part of a tissue shaping device in a manner similar to the anchor of
Distal anchor 480 may be part of a tissue shaping device (such as that shown in
The angle of proximal struts 501 and the angle of distal struts 503 are wider than corresponding angles in the
Distal anchor 500 may be part of a tissue shaping device (such as that shown in
The anchor shown in
Likewise, if distal anchor were to be recaptured into a catheter for redeployment or removal from the patient, anchor 520 would deform about bending points 530 to limit the cross-sectional profile of the anchor within the catheter. Bending points may also be provided on the proximal anchor in a similar fashion.
Anchor 540 is similar to anchor 120 shown in
Tandem anchors 520 and 540 may be part of a tissue shaping device (such as that shown in
While the anchor designs above were described as part of shorter tissue shaping devices, these anchors may be used in tissue shaping devices of any length.
Other connector shapes are possible for an integral connector and crimp design, of course. For example, the device may be formed from a blank shaped as a flat ribbon or sheet by removing rectangular edge sections from a central section, creating an I-shaped sheet (e.g., nitinol or stainless steel) having greater widths at the ends and a narrower width in the center connector portion. The ends can then be rolled to form the crimp tubes, leaving the connector substantially flat. In addition, in alternative embodiments, the connector can be made integral with just one of the anchors.
As shown in
A proximal anchor 572 is also formed in a figure eight configuration from flexible wire such as nitinol with an eyelet 574 on its proximal end. A distally directed actuation force on eyelet 574 moves it over a lock bump 576 extending proximally from crimp tube 564 to actuate and lock anchor 572. Lock bump 576 also serves as the connection point for a tether or control wire to deploy and actuate device in the manner described above with respect to
When deployed in the coronary sinus to treat mitral valve regurgitation, the tissue shaping devices of this invention are subjected to cyclic bending and tensile loading as the patient's heart beats.
Connector 600 has a proximal anchor area 602, a distal anchor area 604 and a central area 606. The distal anchor area may be longer than the distal anchor attached to it, and the proximal anchor area may be longer than the proximal anchor attached to it. An optional lock bump 608 may be formed at the proximal end of connector 600 for use with an actuatable proximal anchor and for connecting to a tether or control wire, as described above. An optional bulb 610 may be formed at the distal end of connector 600 to prevent accidental distal slippage of a distal anchor.
In order to reduce material fatigue caused by the heartbeat to heartbeat loading and unloading of the tissue shaping device, the moment of inertia of connector 600 varies along its length, particularly in the portion of connector disposed between the two anchors. In this embodiment, for example, connector 600 is formed as a ribbon or sheet and is preferably formed from nitinol having a rectangular cross-sectional area. The thickness of connector 600 is preferably constant in the proximal anchor area 602 and the distal anchor area 604 to facilitate attachment of crimps and other components of the anchors. The central area 606 has a decreasing thickness (and therefore a decreasing moment of inertia) from the border between central area 606 and proximal anchor area 602 to a point about at the center of central area 606, and an increasing thickness (and increasing moment of inertia) from that point to the border between central area 606 and distal anchor area 604. The varying thickness and varying cross-sectional shape of connector 600 change its moment of inertia along its length, thereby helping distribute over a wider area any strain from the heartbeat to heartbeat loading and unloading of the device and reducing the chance of fatigue failure of the connector material.
Like the
In the embodiment shown in
In the embodiment shown in
In other embodiments, the thickness of the connector may vary in other ways. In addition, the cross-sectional shape of the connector may be other than rectangular and may change over the length of the connector.
Bending points 712 are formed in the loops of proximal anchor 702, and bending points 714 are formed in the loops of distal anchor 704. When compressed into their unexpanded configurations for catheter-based delivery and deployment or for recapture into a catheter for redeployment or removal, the wire portions of anchors 702 and 704 bend about bending points 712 and 714, respectively, to limit the cross-sectional profile of the anchors within the catheter. The bending points also affect the anchor strength of the anchors and the adaptability of the anchors to different vessel diameters, as discussed above.
In addition to different coronary sinus lengths and varying distances from the ostium to the crossover point between the coronary sinus and the circumflex artery, the diameter of the coronary sinus at the distal and proximal anchor points can vary from patient to patient. The anchors described above may be made in a variety of heights and combined with connectors of varying lengths to accommodate this patient to patient variation. For example, tissue shaping devices deployed in the coronary sinus to treat mitral valve regurgitation can have distal anchor heights ranging from about 7 mm. to about 16 mm. and proximal anchor heights ranging from about 9 mm. to about 20 mm.
When treating a patient for mitral valve regurgitation, estimates can be made of the appropriate length for a tissue shaping device as well as appropriate anchor heights for the distal and proximal anchors. The clinician can then select a tissue shaping device having the appropriate length and anchor sizes from a set or sets of devices with different lengths and different anchor sizes, made, e.g., according to the embodiments described above. These device sets may be aggregated into sets or kits or may simply be a collection or inventory of different tissue shaping devices.
One way of estimating the appropriate length and anchor sizes of a tissue shaping device for mitral valve regurgitation is to view a fluoroscopic image of a coronary sinus into which a catheter with fluoroscopically viewable markings has been inserted. The crossover point between the coronary sinus and the circumflex artery can be determined as described above, and the screen size of the coronary sinus length proximal to that point and the coronary sinus diameter at the intended anchor locations can be measured. By also measuring the screen distance of the catheter markings and comparing them to the actual distance between the catheter marking, the length and diameter measures can be scaled to actual size. A tissue shaping device with the appropriate length and anchor sizes can be selected from a set or inventory of devices for deployment in the patient to treat mitral valve regurgitation.
The device of
To treat mitral valve regurgitation, the device's straight portion 902 reshapes the coronary sinus and adjacent tissue to apply an anteriorally directed force through the coronary sinus wall toward the mitral valve 914. Due to the device's design, this reshaping force is applied solely proximal to the crossover point between coronary sinus 908 and the patient's circumflex artery 916, despite the fact at least a part of the device's distal portion 906 and hooked portion 912 are disposed distal to the crossover point.
Other modifications to the inventions claimed below will be apparent to those skilled in the art and are intended to be encompassed by the claims.
Number | Name | Date | Kind |
---|---|---|---|
3974526 | Dardik et al. | Aug 1976 | A |
3995623 | Black et al. | Dec 1976 | A |
4055861 | Carpentier et al. | Nov 1977 | A |
4164046 | Cooley | Aug 1979 | A |
4485816 | Krumme | Dec 1984 | A |
4550870 | Krumme et al. | Nov 1985 | A |
4588395 | Lemelson | May 1986 | A |
4830023 | de Toledo et al. | May 1989 | A |
5061277 | Carpentier et al. | Oct 1991 | A |
5099838 | Bardy | Mar 1992 | A |
5104404 | Wolff | Apr 1992 | A |
5250071 | Palermo | Oct 1993 | A |
5261916 | Engelson | Nov 1993 | A |
5265601 | Mehra | Nov 1993 | A |
5350420 | Cosgrove et al. | Sep 1994 | A |
5433727 | Sideris | Jul 1995 | A |
5441515 | Khosravi et al. | Aug 1995 | A |
5449373 | Pinchasik et al. | Sep 1995 | A |
5454365 | Bonutti | Oct 1995 | A |
5458615 | Klemm et al. | Oct 1995 | A |
5474557 | Mai | Dec 1995 | A |
5507295 | Skidmore | Apr 1996 | A |
5507802 | Imran | Apr 1996 | A |
5514161 | Limousin | May 1996 | A |
5554177 | Kieval et al. | Sep 1996 | A |
5562698 | Parker | Oct 1996 | A |
5575818 | Pinchuk | Nov 1996 | A |
5584867 | Limousin et al. | Dec 1996 | A |
5601600 | Ton | Feb 1997 | A |
5662703 | Yurek et al. | Sep 1997 | A |
5676671 | Inoue | Oct 1997 | A |
5733325 | Robinson et al. | Mar 1998 | A |
5741297 | Simon | Apr 1998 | A |
5752969 | Cunci et al. | May 1998 | A |
5824071 | Nelson et al. | Oct 1998 | A |
5836882 | Frazin | Nov 1998 | A |
5871501 | Leschinsky et al. | Feb 1999 | A |
5891193 | Robinson et al. | Apr 1999 | A |
5895391 | Farnholtz | Apr 1999 | A |
5899882 | Waksman et al. | May 1999 | A |
5908404 | Elliot | Jun 1999 | A |
5928258 | Khan et al. | Jul 1999 | A |
5935161 | Robinson et al. | Aug 1999 | A |
5954761 | Machek et al. | Sep 1999 | A |
5961545 | Lentz et al. | Oct 1999 | A |
5978705 | KenKnight et al. | Nov 1999 | A |
5984944 | Forber | Nov 1999 | A |
6007519 | Rosselli | Dec 1999 | A |
6015402 | Sahota | Jan 2000 | A |
6022371 | Killion | Feb 2000 | A |
6027517 | Crocker et al. | Feb 2000 | A |
6053900 | Brown et al. | Apr 2000 | A |
6056775 | Borghi et al. | May 2000 | A |
6077295 | Limon et al. | Jun 2000 | A |
6077297 | Robinson et al. | Jun 2000 | A |
6080182 | Shaw et al. | Jun 2000 | A |
6086611 | Duffy et al. | Jul 2000 | A |
6096064 | Routh | Aug 2000 | A |
6099549 | Bosma et al. | Aug 2000 | A |
6099552 | Adams | Aug 2000 | A |
6129755 | Mathis et al. | Oct 2000 | A |
6171320 | Monassevitch | Jan 2001 | B1 |
6183512 | Howanec et al. | Feb 2001 | B1 |
6190406 | Duerig et al. | Feb 2001 | B1 |
6200336 | Pavcnik et al. | Mar 2001 | B1 |
6210432 | Solem et al. | Apr 2001 | B1 |
6228098 | Kayan et al. | May 2001 | B1 |
6254628 | Wallace et al. | Jul 2001 | B1 |
6267783 | Letendre et al. | Jul 2001 | B1 |
6275730 | KenKnight et al. | Aug 2001 | B1 |
6312446 | Huebsch et al. | Nov 2001 | B1 |
6334864 | Amplatz et al. | Jan 2002 | B1 |
6342067 | Mathis et al. | Jan 2002 | B1 |
6345198 | Mouchawar et al. | Feb 2002 | B1 |
6352553 | van der Burg et al. | Mar 2002 | B1 |
6352561 | Leopold et al. | Mar 2002 | B1 |
6358195 | Green et al. | Mar 2002 | B1 |
6395017 | Dwyer et al. | May 2002 | B1 |
6402781 | Langberg et al. | Jun 2002 | B1 |
6419696 | Ortiz et al. | Jul 2002 | B1 |
6442427 | Boute et al. | Aug 2002 | B1 |
6464720 | Boatman et al. | Oct 2002 | B2 |
6503271 | Duerig et al. | Jan 2003 | B2 |
6537314 | Langberg et al. | Mar 2003 | B2 |
6562067 | Mathis | May 2003 | B2 |
6569198 | Wilson et al. | May 2003 | B1 |
6589208 | Ewers et al. | Jul 2003 | B2 |
6599314 | Mathis et al. | Jul 2003 | B2 |
6602288 | Cosgrove et al. | Aug 2003 | B1 |
6602289 | Colvin et al. | Aug 2003 | B1 |
6623521 | Steinke et al. | Sep 2003 | B2 |
6626899 | Houser et al. | Sep 2003 | B2 |
6629534 | St. Goar et al. | Oct 2003 | B1 |
6629994 | Gomez et al. | Oct 2003 | B2 |
6643546 | Mathis et al. | Nov 2003 | B2 |
6648881 | KenKnight et al. | Nov 2003 | B2 |
6652538 | Kayan et al. | Nov 2003 | B2 |
6656221 | Taylor et al. | Dec 2003 | B2 |
6676702 | Mathis | Jan 2004 | B2 |
6689164 | Seguin | Feb 2004 | B1 |
6709425 | Gambale et al. | Mar 2004 | B2 |
6716158 | Raman et al. | Apr 2004 | B2 |
6718985 | Hlavka et al. | Apr 2004 | B2 |
6721598 | Helland et al. | Apr 2004 | B1 |
6723038 | Schroeder et al. | Apr 2004 | B1 |
6733521 | Chobotov et al. | May 2004 | B2 |
6743219 | Dwyer et al. | Jun 2004 | B1 |
6764510 | Vidlund et al. | Jul 2004 | B2 |
6773446 | Dwyer et al. | Aug 2004 | B1 |
6776784 | Ginn | Aug 2004 | B2 |
6790231 | Liddicoat et al. | Sep 2004 | B2 |
6793673 | Kowalsky et al. | Sep 2004 | B2 |
6797001 | Mathis et al. | Sep 2004 | B2 |
6800090 | Alferness et al. | Oct 2004 | B2 |
6805128 | Pless et al. | Oct 2004 | B1 |
6810882 | Langberg et al. | Nov 2004 | B2 |
6821297 | Snyders | Nov 2004 | B2 |
6824562 | Mathis et al. | Nov 2004 | B2 |
6827690 | Bardy | Dec 2004 | B2 |
6881220 | Edwin et al. | Apr 2005 | B2 |
6899734 | Castro et al. | May 2005 | B2 |
6908478 | Alferness et al. | Jun 2005 | B2 |
6935404 | Duerig et al. | Aug 2005 | B2 |
6964683 | Kowalsky et al. | Nov 2005 | B2 |
6966926 | Mathis | Nov 2005 | B2 |
7152605 | Khairkhahan et al. | Dec 2006 | B2 |
7175653 | Gaber | Feb 2007 | B2 |
20010018611 | Solem et al. | Aug 2001 | A1 |
20010041899 | Foster | Nov 2001 | A1 |
20010044568 | Langberg et al. | Nov 2001 | A1 |
20010049558 | Liddicoat et al. | Dec 2001 | A1 |
20020016628 | Langberg et al. | Feb 2002 | A1 |
20020042621 | Liddicoat et al. | Apr 2002 | A1 |
20020042651 | Liddicoat et al. | Apr 2002 | A1 |
20020049468 | Streeter et al. | Apr 2002 | A1 |
20020055774 | Liddicoat | May 2002 | A1 |
20020065554 | Streeter | May 2002 | A1 |
20020087173 | Alferness et al. | Jul 2002 | A1 |
20020095167 | Liddicoat et al. | Jul 2002 | A1 |
20020103533 | Langberg et al. | Aug 2002 | A1 |
20020138044 | Streeter et al. | Sep 2002 | A1 |
20020151961 | Lashinski et al. | Oct 2002 | A1 |
20020156526 | Hlavka et al. | Oct 2002 | A1 |
20020161377 | Rabkin et al. | Oct 2002 | A1 |
20020183837 | Streeter et al. | Dec 2002 | A1 |
20020183838 | Liddicoat et al. | Dec 2002 | A1 |
20020183841 | Cohn et al. | Dec 2002 | A1 |
20020188170 | Santamore et al. | Dec 2002 | A1 |
20030018358 | Saadat | Jan 2003 | A1 |
20030040771 | Hyodoh et al. | Feb 2003 | A1 |
20030069636 | Solem et al. | Apr 2003 | A1 |
20030078465 | Pai et al. | Apr 2003 | A1 |
20030078654 | Taylor et al. | Apr 2003 | A1 |
20030083538 | Adams et al. | May 2003 | A1 |
20030083613 | Schaer | May 2003 | A1 |
20030088305 | Van Schie et al. | May 2003 | A1 |
20030130730 | Cohn et al. | Jul 2003 | A1 |
20030135267 | Solem et al. | Jul 2003 | A1 |
20030144697 | Mathis et al. | Jul 2003 | A1 |
20030171776 | Adams et al. | Sep 2003 | A1 |
20030225454 | Mathis et al. | Dec 2003 | A1 |
20030236569 | Mathis et al. | Dec 2003 | A1 |
20040010305 | Alferness et al. | Jan 2004 | A1 |
20040019377 | Taylor et al. | Jan 2004 | A1 |
20040039443 | Solem et al. | Feb 2004 | A1 |
20040073302 | Rourke et al. | Apr 2004 | A1 |
20040098116 | Callas et al. | May 2004 | A1 |
20040102839 | Cohn et al. | May 2004 | A1 |
20040102840 | Solem et al. | May 2004 | A1 |
20040111095 | Gordon et al. | Jun 2004 | A1 |
20040127982 | Machold et al. | Jul 2004 | A1 |
20040133220 | Lashinski et al. | Jul 2004 | A1 |
20040133240 | Adams et al. | Jul 2004 | A1 |
20040133273 | Cox | Jul 2004 | A1 |
20040138744 | Lashinski et al. | Jul 2004 | A1 |
20040148019 | Vidlund et al. | Jul 2004 | A1 |
20040148020 | Vidlund et al. | Jul 2004 | A1 |
20040148021 | Cartledge et al. | Jul 2004 | A1 |
20040153147 | Mathis | Aug 2004 | A1 |
20040158321 | Reuter et al. | Aug 2004 | A1 |
20040176840 | Langberg | Sep 2004 | A1 |
20040193191 | Starksen et al. | Sep 2004 | A1 |
20040193260 | Alferness et al. | Sep 2004 | A1 |
20040220654 | Mathis et al. | Nov 2004 | A1 |
20040220657 | Nieminen et al. | Nov 2004 | A1 |
20040249452 | Adams et al. | Dec 2004 | A1 |
20040260342 | Vargas et al. | Dec 2004 | A1 |
20050004667 | Swinford et al. | Jan 2005 | A1 |
20050010240 | Mathis et al. | Jan 2005 | A1 |
20050021121 | Reuter et al. | Jan 2005 | A1 |
20050027351 | Reuter et al. | Feb 2005 | A1 |
20050027353 | Alferness et al. | Feb 2005 | A1 |
20050033419 | Alferness et al. | Feb 2005 | A1 |
20050038507 | Alferness et al. | Feb 2005 | A1 |
20050060030 | Lashinski et al. | Mar 2005 | A1 |
20050065598 | Mathis et al. | Mar 2005 | A1 |
20050085903 | Lau | Apr 2005 | A1 |
20050096666 | Gordon et al. | May 2005 | A1 |
20050096740 | Langberg et al. | May 2005 | A1 |
20050107810 | Morales et al. | May 2005 | A1 |
20050119673 | Gordon et al. | Jun 2005 | A1 |
20050137449 | Nieminen et al. | Jun 2005 | A1 |
20050137450 | Aronson et al. | Jun 2005 | A1 |
20050137451 | Gordon et al. | Jun 2005 | A1 |
20050149179 | Mathis et al. | Jul 2005 | A1 |
20050149180 | Mathis et al. | Jul 2005 | A1 |
20050149182 | Alferness et al. | Jul 2005 | A1 |
20050177228 | Solem et al. | Aug 2005 | A1 |
20050187619 | Mathis et al. | Aug 2005 | A1 |
20050197692 | Pai et al. | Sep 2005 | A1 |
20050197693 | Pai et al. | Sep 2005 | A1 |
20050197694 | Pai et al. | Sep 2005 | A1 |
20050209690 | Mathis et al. | Sep 2005 | A1 |
20050216077 | Mathis et al. | Sep 2005 | A1 |
20050261704 | Mathis | Nov 2005 | A1 |
20050272969 | Alferness et al. | Dec 2005 | A1 |
20060020335 | Kowalsky et al. | Jan 2006 | A1 |
20060030882 | Adams et al. | Feb 2006 | A1 |
20060041305 | Lauterjung | Feb 2006 | A1 |
20060116758 | Swinford et al. | Jun 2006 | A1 |
20060142854 | Alferness et al. | Jun 2006 | A1 |
20060161169 | Nieminen et al. | Jul 2006 | A1 |
20060167544 | Nieminen et al. | Jul 2006 | A1 |
20060173536 | Mathis et al. | Aug 2006 | A1 |
20070066879 | Mathis et al. | Mar 2007 | A1 |
Number | Date | Country |
---|---|---|
0893133 | Jan 1999 | EP |
0903110 | Mar 1999 | EP |
0968688 | Jan 2000 | EP |
1050274 | Nov 2000 | EP |
1095634 | May 2001 | EP |
0741604 | Dec 1955 | GB |
2754067 | Mar 1998 | JP |
2000-308652 | Nov 2000 | JP |
2001-503291 | Mar 2001 | JP |
2003-503101 | Jan 2003 | JP |
2003-521310 | Jul 2003 | JP |
9902455 | Dec 2000 | SE |
WO 9856435 | Dec 1998 | WO |
WO 0044313 | Aug 2000 | WO |
WO 0060995 | Oct 2000 | WO |
WO 0060995 | Oct 2000 | WO |
WO 0074603 | Dec 2000 | WO |
WO 0100111 | Jan 2001 | WO |
WO 0119292 | Mar 2001 | WO |
WO 0150985 | Jul 2001 | WO |
WO 0154618 | Aug 2001 | WO |
WO 0187180 | Nov 2001 | WO |
WO 0200099 | Jan 2002 | WO |
WO 0201999 | Jan 2002 | WO |
WO 0205888 | Jan 2002 | WO |
WO 0219951 | Mar 2002 | WO |
WO 0234118 | May 2002 | WO |
WO 0247539 | Jun 2002 | WO |
WO 02053206 | Jul 2002 | WO |
WO 02060352 | Aug 2002 | WO |
WO 02062263 | Aug 2002 | WO |
WO 02062270 | Aug 2002 | WO |
WO 02062408 | Aug 2002 | WO |
WO 02076284 | Oct 2002 | WO |
WO 02078576 | Oct 2002 | WO |
WO 02096275 | Dec 2002 | WO |
WO 03015611 | Feb 2003 | WO |
WO 03037171 | May 2003 | WO |
WO 03049647 | Jun 2003 | WO |
WO 03049648 | Jun 2003 | WO |
WO 03055417 | Jul 2003 | WO |
WO 03059198 | Jul 2003 | WO |
WO 03063735 | Aug 2003 | WO |
WO 2004045463 | Jun 2004 | WO |
WO 2004084746 | Oct 2004 | WO |
WO 2005046531 | May 2005 | WO |
Number | Date | Country | |
---|---|---|---|
20050137685 A1 | Jun 2005 | US |